Independent
Tenure on this board
5.4 yrs
Also a director at
Celldex Therapeutics Inc (CLDX)Seaport Therapeutics Inc (SPTX)
Meeting calendar
GKOS · Annual meeting · Thursday, May 28, 2026
Glaukos Corp
2 nominees · 3 ballot items.
Elect two Class II directors; advisory vote to approve named executive officer compensation; ratify Ernst & Young LLP as independent registered public accounting firm.
Market cap
$9.1B
1Y TSR
+45.0%
Board grade
B-
Record date
Apr 2, 2026
Filing
DEF 14A
Meeting concluded · May 28, 2026
Follow how the vote landed and what changed on Glaukos Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect two Class II director nominees (Denice M. Torres and Aimee S. Weisner) to serve until the 2029 annual meeting.
- 2
Advisory Approval of Named Executive Officer Compensation (Say-on-Pay
ManagementBoard: FORNon-binding, advisory vote to approve the compensation of the Company's named executive officers as disclosed in the proxy statement.
More detail
This proposal asks shareholders to approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement. Management seeks this endorsement to confirm stockholder support for its compensation philosophy and to inform future compensation decisions; the CNG Committee uses the advisory vote results when setting compensation. The proposal is routine, reflects extensive disclosure on pay structure, including performance-based equity, time-based awards, bonus structure and clawback/ownership policies, and is supported by the Board because the compensation program is designed to align executive pay with company strategy, revenue growth and long-term value creation. Context includes high stockholder approval in prior years (98% in 2025), strong 2025 performance with net sales growth and the company’s shift to tie a significant portion of pay to performance metrics; management’s recommendation is 'FOR' with rationale that the program balances retention, performance incentives and governance safeguards.
- 3
Ratification of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
12.1 yrs
Also a director at
Lensar Inc (LNSR)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10.6% | 6,242,027 | $672M |
| 2 | JANUS HENDERSON GROUP PLC | 8.6% | 5,071,438 | $546M |
| 3 | PRIMECAP MANAGEMENT CO/CA/ | 5.7% | 3,370,628 | $363M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.5% | 3,208,363 | $345M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 2,508,771 | $270M |
| 6 | STATE STREET CORP | 3.7% | 2,182,617 | $235M |
| 7 | BlackRock, Inc. | 3.0% | 1,765,299 | $190M |
| 8 | ALLIANCEBERNSTEIN L.P. | 2.4% | 1,397,556 | $158M |
| 9 | Holocene Advisors, LP | 2.4% | 1,383,715 | $149M |
| 10 | CITADEL ADVISORS LLC | 2.4% | 1,382,067 | $149M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Glaukos Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.8B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.2B
Reference
Frequently asked questions
- When is the Glaukos Corp 2026 annual meeting?
- Glaukos Corp (GKOS) holds its 2026 annual shareholder meeting on Thursday, May 28, 2026.
- What is the record date for the Glaukos Corp 2026 meeting?
- The record date for the Glaukos Corp 2026 meeting is Thursday, April 2, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Glaukos Corp's 2026 meeting?
- The board is presenting 2 director nominees at the Glaukos Corp 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Glaukos Corp 2026 meeting?
- Shareholders will vote on 3 proposals at the Glaukos Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.